| 6.44 -0.07 (-1.08%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.33 | 1-year : | 10.69 |
| Resists | First : | 7.99 | Second : | 9.15 |
| Pivot price | 7.64 |
|||
| Supports | First : | 6.09 | Second : | 5.07 |
| MAs | MA(5) : | 6.65 |
MA(20) : | 7.79 |
| MA(100) : | 7.63 |
MA(250) : | 10.29 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.1  |
D(3) : | 5.3 |
| RSI | RSI(14): 36 |
|||
| 52-week | High : | 25.38 | Low : | 6.09 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BCYC ] has closed above bottom band by 10.7%. Bollinger Bands are 116.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.56 - 6.6 | 6.6 - 6.63 |
| Low: | 6.08 - 6.13 | 6.13 - 6.17 |
| Close: | 6.36 - 6.44 | 6.44 - 6.5 |
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Thu, 06 Nov 2025
Institutional Owners May Take Dramatic Actions as Bicycle Therapeutics Plc's (NASDAQ:BCYC) Recent 25% Drop Adds to One-year Losses - 富途牛牛
Fri, 31 Oct 2025
Citizens Maintains Bicycle Therapeutics plc - Depositary Receipt (BCYC) Market Outperform Recommendation - Nasdaq
Fri, 31 Oct 2025
Bicycle Therapeutics (BCYC): RBC Capital Downgrades and Lowers P - GuruFocus
Thu, 30 Oct 2025
BICYCLE THERAPEUTICS PLC SEC 10-Q Report - TradingView
Mon, 27 Oct 2025
Bicycle Therapeutics PLC Sponsored ADR $BCYC Position Boosted by Tybourne Capital Management HK Ltd. - MarketBeat
Wed, 15 Oct 2025
Bicycle Therapeutics: Looking For Their Niche, Addressing Cash Burn (NASDAQ:BCYC) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 1.3 (%) |
| Shares Short | 1,460 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.8111e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 965.8 % |
| Return on Equity (ttm) | -19.1 % |
| Qtrly Rev. Growth | 1.928e+007 % |
| Gross Profit (p.s.) | -46.81 |
| Sales Per Share | -21.38 |
| EBITDA (p.s.) | -1.42075e+008 |
| Qtrly Earnings Growth | -3.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -208 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.31 |
| Price to Cash Flow | 0.98 |
| Dividend | 0 |
| Forward Dividend | 1.54e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|